Absci Corporation (ABSI) announced a strategic collaboration with AMD (AMD) to deploy AMD Instinct accelerators and ROCm software to power critical AI drug discovery workloads, including Absci’s advanced de novo antibody design models. AMD will also make a $20M investment in Absci, structured as a private investment in public equity, PIPE, underscoring the growing demand for innovative AI applications in drug discovery.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on ABSI:
- Absci price target lowered to $5 from $6 at KeyBanc
- Absci, Invetx partner to bring AI drug creation platform to animal health
- Absci highlights progress, updates across proprietary pipeline
- Cathie Wood’s ARK Investment bought 202.6K shares of Absci today
- Cathie Wood’s ARK Investment bought 137.9K shares of Absci today
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
